Novartis is 'all in' on siRNA, inking a new collaboration with Alnylam to develop alternative to liver transplants

Nicole DeFeudis

Editor

Alnylam was a few years ahead in the small interfering RNA (siRNA) space when Novartis jumped on the bandwagon in early 2020, licensing the company’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis is 'all in' on siRNA, inking a new collaboration with Alnylam to develop alternative to liver transplants

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

FDA lifts hold on Entrada's Duchenne drug after two years

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

How AI can address ongoing challenges in the life sciences industry

No­var­tis is 'all in' on siR­NA, ink­ing a new col­lab­o­ra­tion with Al­ny­lam to de­vel­op al­ter­na­tive to liv­er trans­plants

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis is 'all in' on siRNA, inking a new collaboration with Alnylam to develop alternative to liver transplants